Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.86+1.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RCKT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name operates in a high-miss-rate industry and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
RCKT — earnings miss
Dated 2026-08-10
and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Why it matters: Completing the PRV sale is key for funding operations into 2028. It shows financial stability.
Supportive ifThe sale of the PRV is now complete.
Worry ifNo announcement of the PRV sale completion by the next earnings date.
Why it matters: The PRV sale helps the company’s finances. This affects its ability to run operations.
Supportive ifConfirmation that cash runway extends into the second quarter of 2028 post-PRV sale.
Worry ifCash runway guidance is lowered or the cash position gets worse.
Why it matters: Watching losses and cash burn is important. It helps check financial health and stability.
Worry ifOperating losses are much lower than in previous quarters.
Less concerning ifOperating losses are higher or stay the same. This shows worsening financial health.
Why it matters: Completing the PRV sale would show progress in funding operations and plans.
Supportive ifAn announcement will confirm the PRV sale is done and funds are received.
Worry ifNo announcement or delay in finishing the PRV sale.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$207 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $593 loss on $10,000 · 5.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,094 loss on $10,000 · 50.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Dosing the first patient shows progress in Rocket's heart treatments. It also supports its plan.
Supportive ifAnnouncement of the first patient being dosed in the Phase 1 study of RP-A701.
Worry ifDelay in patient dosing or further setbacks in the trial timeline.
Why it matters: A new rule may show progress in Rocket's PKP2 treatment efforts.
Supportive ifRocket shares a regulatory update on a key study for RP-A601.
Worry ifNo regulatory update is provided by the end of 2026.
Why it matters: News about cash and operations can change how investors feel. It may also affect funding plans.
Watch forThe cash position is over $322 million after the PRV sale.
Also watch forThe cash position is under $300 million or there are unexpected costs.
Why it matters: Completion of the pivotal trial is crucial for advancing treatment for Danon disease. It could lead to regulatory approval.
Supportive ifRocket announces alignment with the FDA on the path to dosing additional patients for RP-A501.
Worry ifNo updates from Rocket regarding FDA alignment or trial completion by the end of 2026.
Why it matters: Updates will show if Rocket can keep running and fund its projects.
Watch forIt is confirmed that cash and investments are enough to fund operations until Q2 2028.
Also watch forNew guidance shows a shorter cash runway than before.
Why it matters: Rocket has reported zero revenue. Any growth signals future potential.
Supportive ifQ2 earnings report shows any revenue greater than zero.
Worry ifRevenue remains zero in the Q2 earnings report.
Why it matters: This would show that cash burn is worsening, impacting funding plans.
Worry ifQ2 losses are more than $50 million.
Less concerning ifQ2 losses are less than $50 million.
Why it matters: Cash burn is critical for Rocket's survival. High losses may affect funding plans.
Worry ifQ2 earnings report shows cash burn less than $45 million.
Less concerning ifCash burn exceeds $45 million in the Q2 earnings report.
Why it matters: An update from the FDA could confirm the path for additional patient dosing and trial completion.
Supportive ifA press release confirming alignment with the FDA on the path to complete the pivotal trial.
Worry ifNo update or further delays in the regulatory process for RP-A501.
Why it matters: Successful sales would support Rocket's plan. It would also help its money situation.
Supportive ifAnnouncement for KRESLADI's launch and details on the first patients.
Worry ifDelays or problems in selling KRESLADI.
Why it matters: A detailed update can show how the trial is going. It may also show future steps.
Watch forA webinar or press release detailing the Danon disease program and trial results.
Also watch forNo update or negative findings shared during the update.